Cefpodoxime and Cefdinir Show Similar UTI Outcomes
A retrospective study presented at IDWeek 2026 found comparable treatment failure rates for two oral antibiotics in emergency department patients.
Updated on Nov. 3, 2026 in COVID-19
Researchers presenting at IDWeek 2026 compared cefpodoxime and cefdinir in adults discharged from the emergency department with urinary tract infections. Treatment failure rates were similar at 14, 28 and 90 days.
Why it matters
Few head-to-head comparisons of these agents exist for patients discharged from the emergency department with UTIs. The findings add evidence to a question clinicians face when choosing oral outpatient therapy.
The evidence comes from a retrospective cohort at MedStar Washington Hospital Center covering July 2024 to October 2025. Complicated UTI rates were 42.9% for cefpodoxime versus 30.7% for cefdinir, and appropriate dosing occurred in 50.2% of cefdinir patients versus 29.5% of cefpodoxime patients, while the study's design leaves causal links and the exploratory cefazolin subgroup results unconfirmed.
The players
MedStar Washington Hospital Center
A large academic medical center in Washington, D.C., which served as the single site for the retrospective emergency department study.
IDWeek
An annual meeting of the Infectious Diseases Society of America and allied societies, where infectious disease researchers present clinical and scientific findings.
The details
The researchers reviewed adults discharged from the emergency department with a UTI and defined treatment failure as a return to care for urinary symptoms or an antibiotic switch, escalation or reinitiation for persistent or worsening symptoms. Cefpodoxime-treated patients had higher rates of complicated infections, and the authors note that the difference in appropriate dosing may bear on outcomes.
Timeline
July 2024: Patient inclusion period begins at MedStar Washington Hospital Center.
October 2025: Patient inclusion period ends.
October 21-24, 2026: Results are presented at IDWeek 2026.
Health Landscape
The comparison adds to a growing set of stewardship studies at IDWeek examining narrower oral options for common outpatient infections. It reflects a broader effort to weigh oral beta-lactams against alternatives when clinicians seek to limit broad-spectrum antibiotic use in emergency discharges.
For patients discharged from the emergency department with a UTI, the findings suggest that the choice between these two oral antibiotics may produce similar short-term outcomes in this setting. Patients should follow the dosing instructions their clinician provides, since appropriate dosing differed between the two groups in the study.
The takeaway
Both antibiotics showed comparable treatment failure rates in this single-center study, but differences in complicated infections and dosing suggest that prescribing details deserve attention alongside drug choice.
Further reading
For related coverage of infection-treatment research, see the COVID-19 section.
